New imaging agent shows promise for detecting Hard-to-Treat cancers
NCT ID NCT04712721
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times
Summary
This study tested a new imaging agent called 68Ga-FF58 in 14 adults with certain advanced solid tumors, including glioblastoma and pancreatic cancer. The goal was to see how well it shows up on PET/CT scans and to check its safety. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Lyon, 69373, France
-
Novartis Investigative Site
Essen, 45147, Germany
Conditions
Explore the condition pages connected to this study.